Eosinophilic gastritis and duodenitis with esophageal involvement becoming clinically apparent during long-term omalizumab therapy and successfully treated with dupilumab
Clinical Journal of Gastroenterology · 16.11.2026
DOI: 10.1007/s12328-026-02488-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of Gastroenterology, online erschienen am 16.11.2026. Verfasst von Yasuhiko Abe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endoscopy, Yamagata University Hospital, 2-2-2 Iida-Nishi, Yamagata-Shi, Yamagata, 990-9585, Japan. y-abe@med.id.yamagata-u.ac.jp. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
We present a case of non-eosinophilic esophagitis eosinophilic gastrointestinal diseases (non-EoE EGIDs) that became clinically apparent during long-term anti-immunoglobulin E (IgE) therapy with omalizumab for bronchial asthma (BA). A 53-year-old woman with severe BA, atopic dermatitis, multiple drug allergies, and diabetes mellitus presented with upper abdominal discomfort. Her asthma had been well controlled for more than 10 years with omalizumab. Initial esophagogastroduodenoscopy revealed mild edema in the distal esophagus and patchy discolored areas in the lower gastric body. Gastric biopsy showed marked eosinophilic infiltration, and non-EoE EGIDs were suspected. Although her symptoms initially improved after montelukast initiation, they worsened 6 months later. Repeat endoscopy showed persistent esophageal edema and gastric discoloration and newly detected erythema in the gastric antrum. Biopsy demonstrated pathological eosinophilic infiltration in the distal esophagus, stomach, and duodenum. She was diagnosed with eosinophilic gastritis and eosinophilic duodenitis with esophageal involvement, considered to have become clinically apparent during long-term omalizumab treatment. Omalizumab was switched to dupilumab, and her abdominal symptoms improved within 1 month. Follow-up 5 months later confirmed endoscopic improvement and histological remission. In conclusion, anti-IgE therapy may be insufficient to control gastrointestinal eosinophilic inflammation, and switching to dupilumab may be effective in selected patients with non-EoE EGIDs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Endoscopy, Yamagata University Hospital, 2-2-2 Iida-Nishi, Yamagata-Shi, Yamagata, 990-9585, Japan. y-abe@med.id.yamagata-u.ac.jp.
- Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
- Division of Endoscopy, Yamagata University Hospital, 2-2-2 Iida-Nishi, Yamagata-Shi, Yamagata, 990-9585, Japan.
Zitieren
APA
Abe, Y., Onozato, Y., Goto, H., Ito, M., Nagata, D., Itagaki, H., Sato, S., Mizumoto, N., Yagi, M., & Sasaki, Y. (2026). Eosinophilic gastritis and duodenitis with esophageal involvement becoming clinically apparent during long-term omalizumab therapy and successfully treated with dupilumab. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-026-02488-w
Vancouver
Abe Y, Onozato Y, Goto H, Ito M, Nagata D, Itagaki H, et al. Eosinophilic gastritis and duodenitis with esophageal involvement becoming clinically apparent during long-term omalizumab therapy and successfully treated with dupilumab. Clinical Journal of Gastroenterology. 2026. doi:10.1007/s12328-026-02488-w
BibTeX
@article{Abe2026,
author = {Abe, Yasuhiko and Onozato, Yusuke and Goto, Hiroki and Ito, Minami and Nagata, Daiki and Itagaki, Hideki and Sato, Shingo and Mizumoto, Naoko and Yagi, Makoto and Sasaki, Yu},
title = {Eosinophilic gastritis and duodenitis with esophageal involvement becoming clinically apparent during long-term omalizumab therapy and successfully treated with dupilumab},
journal = {Clinical Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s12328-026-02488-w}
}
EUVIMED